Related Experiment Video
Updated: Sep 17, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Rapid valve sterilization with meropenem plus ceftolozane/tazobactam combination therapy for Pseudomonas aeruginosa
Valliammai Alaguvel1, Anuj K Khetarpal1, Allen Jankeel1
1Department of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Background:
Pseudomonas aeruginosa infective endocarditis (IE) presents a significant clinical challenge, leading to high rates of treatment failure and mortality. Even with the use of antipseudomonal β-lactams combined with aminoglycosides or fluoroquinolones, these therapies often fail to provide clinical resolution and are frequently accompanied by severe adverse effects.
Methods:
We report a case of P. aeruginosa prosthetic valve endocarditis successfully treated with a combination of meropenem and ceftolozane/tazobactam. To investigate the synergistic effects of this combination, we conducted checkerboard, time-kill, human whole blood killing, and biofilm assays, as well as a simulated endocardial vegetation (SEV) model.
Results:
Meropenem plus ceftolozane/tazobactam combination therapy successfully bridged the patient to cardiac surgery, achieving rapid microbiological clearance and sterile intraoperative valve cultures. While checkerboard assays showed additivity, time-kill assays with subtherapeutic antibiotic concentrations did not demonstrate synergy in standard media. However, significant synergy was observed in human whole blood and biofilm environments, with modestly improved activity in the SEV model.
Conclusions:
The combination of meropenem and ceftolozane/tazobactam demonstrates promising synergy in physiologically relevant conditions, offering a potentially safer alternative for treating P. aeruginosa IE and stabilizing complex patients prior to cardiac surgery. Further clinical investigation is needed to evaluate its efficacy and safety profile in severe Pseudomonas infections, including IE.
Insights
This study shows that combining meropenem and ceftolozane/tazobactam effectively treated Pseudomonas aeruginosa prosthetic valve endocarditis. The combination demonstrated synergy in human blood and biofilm, offering a promising alternative for challenging infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- * Pseudomonas aeruginosa infective endocarditis (IE) is a severe condition with high treatment failure and mortality rates.
- * Current therapies, including antipseudomonal β-lactams with aminoglycosides or fluoroquinolones, often lack efficacy and cause adverse effects.
Purpose of the Study:
- * To report a case of P. aeruginosa prosthetic valve endocarditis successfully treated with meropenem and ceftolozane/tazobactam.
- * To investigate the synergistic effects of this antibiotic combination in various in vitro and ex vivo models.
Main Methods:
- * Case report of P. aeruginosa prosthetic valve endocarditis.
- * In vitro assays: checkerboard, time-kill, human whole blood killing, and biofilm assays.
- * Ex vivo model: simulated endocardial vegetation (SEV) model.
Main Results:
- * Meropenem plus ceftolozane/tazobactam achieved microbiological clearance and facilitated cardiac surgery.
- * Synergy was observed in human whole blood and biofilm assays, and modestly in the SEV model.
- * Additivity was noted in checkerboard assays; synergy was absent in standard time-kill assays.
Conclusions:
- * The combination of meropenem and ceftolozane/tazobactam shows promising synergistic activity in conditions mimicking the human body.
- * This combination may offer a safer alternative for treating P. aeruginosa IE and stabilizing patients before surgery.
- * Further clinical trials are warranted to confirm efficacy and safety in severe Pseudomonas infections.
More Related Videos
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Mitral Stenosis III: Medical Management
Endocarditis I: Introduction
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management

